key: cord-0987769-q4m7nkh2 authors: SABNIS, R.; Patil, A.; Shete, N.; Rastogi, A. K. title: Breakthrough COVID-19 infection rate with Indian strain in Single-center Healthcare Workers: A real world data. date: 2021-07-07 journal: nan DOI: 10.1101/2021.07.02.21258881 sha: b57deffdb6daefb46d73f20be618629a4ba3d352 doc_id: 987769 cord_uid: q4m7nkh2 Abstract: Introduction: It is observed that many healthcare workers got COVID19 infection despite of completing both doses of Covishield vaccine. This study aimed to find real incidence of vaccine breakthrough infection. Material and methods: All hospital employees, who were fully vaccinated were included in study. Details about their vaccine side effects, infection prior to vaccination, post vaccination infection, severity of infection, hospital and ICU admission were noted. Results: None encountered any significant side effects of vaccine. Of the 461 participants, 86 (18.65%) got infection average 38 days (range 14 to 70days) after vaccination. As per the NIH classification, out of 86, disease was mild in 69(80.2%), moderate in 10(11.62%), severe in 6(6.97%) and critical in 1(1.16%). Of these, 10(11.62%) required hospital admission. Of these 10, 2 were shifted to ICU. Of the 2, One recovered while one died. Thus mortality was 1/86(1.6%). Conclusion: Breakthrough infection rate in health care workers was 18.65%. Moderate, severe or critical disease occurred in 19.7% participants even after two doses of vaccine. Mortality due to disease cannot be completely obviated due to vaccine. The vaccine was safe without any significant adverse events. This was a prospective study involving all the health care workers at a tertiary health care center. All the health care workers working at our institute were vaccinated with two . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2021. doses of Covishield (SII-ChAdOx1 nCoV-19) administered on Days 1 and 29 as 0.5 ml dose intramuscularly. As a hospital policy, hospital maintained the health-related data from COVID-19 point of view of all employees after vaccination. If any information was lacking or more details were required, that employee was contacted to obtain it. The institutional ethical approval was achieved. All the healthcare workers more than age 18 years who voluntarily consented for vaccine and data analysis were included in the study. The health-related data was retrieved from the hospital registry after consent of the participant. The data was collected from first Severe Illness: Individuals who have SpO2 <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%. Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction. The statistical analysis was done using software IBM SPSS version 25 (IBM, Armonk, NY, USA). Quantitative variables were described as mean±SD while qualitative variables were described as %. Significance of qualitative variables were tested using proportion test. p-value of less than 0.05 was considered to be significant. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. nurses/technicians and 40/86 (46.5%) were para-medical staff. 9/86 (10.6%) participants had co-morbidities (Diabetes milletus in 4, hypertension in 6, ischemic heart disease in 1). The infection was mild in 69/86 (80.2%), moderate in 10/86 (11.62%), severe in 6/86 (6.97%) and critical in 1/86 (1.16%). Of these, 10 (11.62%) required hospital admission. The indications for hospital admissions were -prolonged lower respiratory symptoms, significant lung involvement with blood abnormalities, requirement of IV medications, dyspnoea or oxygen saturation falling below 94. Of these 10 hospitalized patients, 2 had to be shifted to ICU for high flow oxygen & respiratory failure. Of these 2, one recovered and the other required ventilatory support due to falling saturation and despite all the efforts, this patient died. Thus, mortality rate in our study population was 1/86 (1.16%) -this was a healthcare worker with only hypertension as comorbidity and symptoms of cough, body ache, malaise after 31 days of second dose of vaccination. Later developed dyspnoea on walking & had blood abnormalities. Initially was managed conservatively with oral medications. But needed hospitalization for IV steroids and oxygen supplementation for dyspnoea. Patient was shifted . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.02.21258881 doi: medRxiv preprint to intensive care unit and required ventilatory support, but died on 7 th day of infection. There was severe disease in 7/86 (8.13%) patients requiring oxygen supplementation for variable period of time from 12 hrs to 72 hrs. All the family members of two healthcare workers were infected with COVID-19. None of these family members were vaccinated. Both the healthcare workers being fully vaccinated had mild disease course. On the contrary, all the affected family members had severe disease with one death of family member in each family. Blood parameters were done in 48/86 (55.81%). Among these 48 participants, Creactive protein(CRP) was raised (Cut off value -7mg/L) in 17 cases. Mean CRP was 23.4 mg/L (range 10-73). d-DIMER (Lab cut off -0.5 mcg/ml) was deranged in 26 cases. Mean d-DIMER was 0.89 mcg/ml(range 0.6 -3.1 mcg/ml). Chest CT scan was performed in 21 participants, which was abnormal in 18 participants (CT severity score -5 to 16/25). Out of these 40 previously infected participants, 10(25%) had break-through infection. All had received both doses of vaccine. All had mild disease and recovered without any specific treatment. The family members or close contact group were infected in 9/86 (10.46%) postvaccination cohort. However, this infection rate was 11/40(27.5%) in the pre-vaccination era. All eligible hospital employees participated in the study. Thus, removing attrition bias. All the healthcare workers were always available for health update and thus their data was accurate, obviating recall bias. This was the strength of the study. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. infection in family members with similar genetic composition in everybody. This is only observation which requires further evaluation. In our study, family members and close contacts of 10.46% participants were infected in post-vaccination group as against 27.5% infection rate of family members and close contacts in pre-vaccination group. (p=0.029) This suggests that spread from vaccinated people to others is significantly less. This finding is similar to other studies which showed that spreading potential post vaccination was much less. (12, 13) Several studies have proved safety profile of vaccine in trial population. (2, 14, 15) In our study, none had any significant side effects of vaccine, early or late, supporting that vaccine is safe even in real world scenario. The post-vaccine infection rate in health care workers was 18.65%. Moderate, severe or critical disease occurred in 19.7% participants even after two doses of vaccine. Mortality due to disease cannot be completely obviated due to vaccine. The vaccine was safe without any significant adverse events. COVID-19) Situation Reports Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra Tracking SARS-CoV-2 variants Six months of COVID vaccines: what 1.7 billion doses have taught scientists COVID-19 Treatment Guidelines A Real World Evaluation of the safety and immunogenicity of the Covishield vaccine, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India: A preliminary report Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv WHO classifies India variant as being of global concern ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets Impact of vaccination on household transmission of SARS-COV-2 in England Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial